Abstract: Pharmaceutical compositions, kits, and methods are disclosed for use in treating or reducing the occurrence of a viral infection in a patient. The compositions, kits, and methods utilize at least one anti-Pathogenic Host Response (anti-PHR) agent, either alone or in combination with at least one anti-viral agent.

Abstract: Compositions and methods are disclosed for enhancing the bioavailability and/or increasing the stability of at least one agent by modifying the at least one agent with cyclodextrin. Pharmaceutical compositions including the cyclodextrin-modified agents are disclosed. Methods of manufacturing the cyclodextrin-modified agents as well as methods of using the cyclodextrin-modified agents are also disclosed.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: Agonists and antagonists of nAChR?7 and their use as therapeutic agents for treating and managing inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are disclosed.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: The invention provides analgesic, antipyretic, anti-inflammatory, and anti-neoplastic compositions containing epilactose in combination with non-steroidal anti-inflammatory drugs and pharmaceutically acceptable zinc compounds. This invention relates to the use of these novel compositions for significantly improved and synergistic safety and therapeutic profiles.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: Methods, devices, and kits for diagnosing or evaluating irritable bowel syndrome employ an analysis for the presence and amount of specific cytokines. The levels of such cytokines provide an index for diagnosis and/or evaluation of therapeutic response. Samples to be tested include peripheral blood, serum, plasma, or tissue from a human subject having or suspected of having Irritable Bowel Syndrome.

Abstract: Agonists and antagonists of nAChR?7 and their use as therapeutic agents for treating and managing inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are disclosed. Agonists and antagonists of nAChR?7 and their use as therapeutic agents for treating and managing inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are disclosed.

Abstract: Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Abstract: A hydrocarbon synthesis process (10) includes feeding gaseous reactants (18) into a slurry bed (14), allowing the gaseous reactants (18) to react catalytically, thereby to form liquid and gaseous hydrocarbon products, and subjecting a product mixture comprising liquid product and catalyst particles in a filtration stage to filtration, by passing the liquid product through a filtering medium (30) to separate catalyst particles from the liquid product. The gaseous products are withdrawn (23) and cooled to form a multi-phase product which is separated to produce at least a hydrocarbon condensate stream (88) and a tail-gas stream (84). At least a portion of the hydrocarbon condensate stream (88) is treated (96) to remove oxygenated components therefrom, producing a backflush condensate. From time to time, the filtering medium (30) of the filtration stage is backflushed by passing the backflush condensate through the filtering medium (30).

Abstract: A hydrocarbon synthesis process (10) includes feeding gaseous reactants (18) into a slurry bed (14), allowing the gaseous reactants (18) to react catalytically, thereby to form liquid and gaseous hydrocarbon products, and subjecting a product mixture comprising liquid product and catalyst particles in a filtration stage to filtration, by passing the liquid product through a filtering medium (30) to separate catalyst particles from the liquid product. The gaseous products are withdrawn (23) and cooled to form a multi-phase product which is separated to produce at least a hydrocarbon condensate stream (88) and a tail-gas stream (84). At least a portion of the hydrocarbon condensate stream (88) is treated (96) to remove oxygenated components therefrom, producing a backflush condensate. From time to time, the filtering medium (30) of the filtration stage is backflushed by passing the backflush condensate through the filtering medium (30).

Abstract: Quantitative expression datasets are created and used in the identification, monitoring and treatment of disease states and characterization of biological conditions. Quantitative datasets are derived from subject samples and enable evaluation of a biological condition. Such quantitative datasets may be used to provide an output score indicative of the biological state of a subject through analysis against a profile dataset.

Abstract: The invention provides methods for diagnosing, treating, or evaluating inflammatory and autoimmune diseases by sampling peripheral blood, serum, plasma, tissue, cerebrospinal fluid, or other bodily fluids from a human subject having a suspected diagnosis. The sample is analyzed for the presence and amount of certain cytokines, which provides the diagnosis, prognosis or evaluation of therapeutic response.

Abstract: An apparatus for routing power between a set of power supply taps of an automated tester and power connections on an integrated circuit under test, where the integrated circuit belongs to a family of integrated circuits that have a common power connection layout and different power connection voltage requirements. An interface board having first electrical contacts disposed in the common power connection layout makes electrical connections to the power connections of all integrated circuits belonging to the family of integrated circuits. The first electrical contacts are electrically routed to second electrical contacts disposed in a standardized configuration. A power personality card having third electrical contacts makes electrical connections to the second electrical contacts of the interface board.